Infectious Diseases 2022

Infectious Diseases 2022

The economic value of the H7N9 vaccination program in poultry in Guangxi - China

Preventive Veterinary Medicine 200 (2022) 105580 17 January, 2022

Influenza A (H7N9) virus was first isolated from humans in March 2013 in China. It has also been detected in poultry in China in the same month and since then has spread across the country. China launched a series of policies to control the disease since April 2013, including:
(1) a disease surveillance programme in poultry; (2) closing live bird markets (LBMs) and controlling the movement of live poultry when infection in people or poultry were reported; (3) improving biosecurity of LBMs; and (4) the promotion of poultry meat trade to consumers over live bird value chains. Despite these interventions, there was only partial compliance with these measures. Highly pathogenic strains of H7N9 virus have been detected in humans and poultry since January 2017, posing an increased threat of infection.
China launched a H7N9 vaccination program in poultry, starting from the Guangxi and Guangdong provinces inJuly 2017, followed by other provinces in September 2017, as a response to a steep increase of H7N9 influenza human infections from September 2016. Since then, H5-H7 bivalent vaccine has been used in the nation wide avian influenza compulsory vaccination program to replace the existing H5N1 vaccine.
A new study shows the significant economic advantage of implementing a vaccination program against H7N9 in Guangxi. It also offers a new set of evidence to China’s H7N9 vaccination policy and debates around economic values of conducting routine avian influenza vaccination.